Abstract
We have developed a collaborative hospital-based approach to monitoring the impact of a human papillomavirus vaccine on cervical cancer, its precursor lesions and human papillomavirus type-specific prevalence in Japan. The monitoring will be conducted for a total period of 21 years on women aged <40 who are newly diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia or adenocarcinoma in situ at 21 participating institutes. Women are monitored to determine their vaccine history and will be human papillomavirus-genotyped each year. The primary endpoint is the human papillomavirus16/human papillomavirus18-positive rate in women aged 16-25 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ. The major secondary endpoints are the number of women aged <40 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ, the human papillomavirus type-specific prevalence, and the number of deaths from invasive cervical cancer in women aged <40. Long-term surveillance for human papillomavirus-associated cervical diseases in young females is important for the development of future strategies for cervical cancer prevention in Japan.
| Original language | English |
|---|---|
| Pages (from-to) | 1000-1003 |
| Number of pages | 4 |
| Journal | Japanese Journal of Clinical Oncology |
| Volume | 44 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 1 2014 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
Cite this
Monitoring the impact of a national HPV vaccination program in Japan (MINT Study) : rationale, design and methods. / MINT Study Group.
In: Japanese Journal of Clinical Oncology, Vol. 44, No. 10, 01.10.2014, p. 1000-1003.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Monitoring the impact of a national HPV vaccination program in Japan (MINT Study)
T2 - rationale, design and methods
AU - MINT Study Group
AU - Matsumoto, Koji
AU - Yaegashi, Nobuo
AU - Iwata, Takashi
AU - Ariyoshi, Kazuya
AU - Fujiwara, Kiyoshi
AU - Shiroyama, Yuko
AU - Usami, Tomoka
AU - Kawano, Yoshiaki
AU - Horie, Koji
AU - Kawano, Kouichiro
AU - Noda, Kiichiro
AU - Yoshikawa, Hiroyuki
PY - 2014/10/1
Y1 - 2014/10/1
N2 - We have developed a collaborative hospital-based approach to monitoring the impact of a human papillomavirus vaccine on cervical cancer, its precursor lesions and human papillomavirus type-specific prevalence in Japan. The monitoring will be conducted for a total period of 21 years on women aged <40 who are newly diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia or adenocarcinoma in situ at 21 participating institutes. Women are monitored to determine their vaccine history and will be human papillomavirus-genotyped each year. The primary endpoint is the human papillomavirus16/human papillomavirus18-positive rate in women aged 16-25 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ. The major secondary endpoints are the number of women aged <40 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ, the human papillomavirus type-specific prevalence, and the number of deaths from invasive cervical cancer in women aged <40. Long-term surveillance for human papillomavirus-associated cervical diseases in young females is important for the development of future strategies for cervical cancer prevention in Japan.
AB - We have developed a collaborative hospital-based approach to monitoring the impact of a human papillomavirus vaccine on cervical cancer, its precursor lesions and human papillomavirus type-specific prevalence in Japan. The monitoring will be conducted for a total period of 21 years on women aged <40 who are newly diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia or adenocarcinoma in situ at 21 participating institutes. Women are monitored to determine their vaccine history and will be human papillomavirus-genotyped each year. The primary endpoint is the human papillomavirus16/human papillomavirus18-positive rate in women aged 16-25 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ. The major secondary endpoints are the number of women aged <40 who are diagnosed with invasive cervical cancer, cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ, the human papillomavirus type-specific prevalence, and the number of deaths from invasive cervical cancer in women aged <40. Long-term surveillance for human papillomavirus-associated cervical diseases in young females is important for the development of future strategies for cervical cancer prevention in Japan.
UR - http://www.scopus.com/inward/record.url?scp=84922392066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922392066&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyu097
DO - 10.1093/jjco/hyu097
M3 - Article
C2 - 25098705
AN - SCOPUS:84922392066
VL - 44
SP - 1000
EP - 1003
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
SN - 0368-2811
IS - 10
ER -